Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. While the company shows improved financial health, with reduced losses and cash use, and has a strong product pipeline, the market is facing softness and uncertainties. Although there is optimism about new product adoption and sales force expansion, the guidance remains cautious, reflecting macroeconomic headwinds. Furthermore, management's lack of clarity on long-term growth rates adds to uncertainty. The positive aspects are balanced by potential risks, leading to a neutral sentiment.
Key Financial Performance
Revenue (Q4 2025) $62.5 million, a decrease of 9% compared to the prior year period. The decline was mainly driven by the shift in revenue mix towards lower-priced products.
Gross Margin (Q4 2025) 80.6%, compared to 80.7% in Q4 2024. The slight decrease reflects a stable margin performance year-over-year.
Total Operating Expenses (Q4 2025) $56.3 million, compared to $55.7 million in Q4 2024. The increase reflects restructuring charges and increased litigation expenses in the quarter compared to the prior year.
Net Loss (Q4 2025) $9.4 million or $0.15 per share, compared to a net loss of $0.5 million or $0.01 per share in Q4 2024. The increase in net loss is attributed to the shift in revenue mix and higher operating expenses.
Adjusted EBITDA (Q4 2025) $6.2 million, compared to $11.1 million in Q4 2024. The decline reflects the impact of the revenue mix shift and increased expenses.
Adjusted EBITDA (Full Year 2025) Loss of $3.9 million, compared to a loss of $11.0 million in 2024, a 64% improvement due to reduced cash usage and operating expense management.
Cash Usage (Full Year 2025) $27.3 million, a decrease of 46% compared to $50.5 million in 2024, driven by cost-saving measures and operational efficiencies.
Cash, Cash Equivalents, and Marketable Securities (End of 2025) $48.4 million, supported by a new credit facility providing an additional $115 million of liquidity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Bunion Procedure Innovations: Commercialized multiple new bunion procedure innovations, addressing 100% of surgeons' technique preferences for bunion correction with 5 instrumented systems.
Nanoplasty and Percuplasty 3D MIS Systems: Expanded reach into the high-volume osteotomy segment, offering less pain, faster recovery, and minimal scars for patients. These systems target 70% of the 450,000 annual U.S. bunion procedures.
SpeedMTP System: Designed for 20% of bunion patients with arthritic grade toe or MTP joints, addressing a large patient population.
Lapiplasty Lightning: Next-generation Lapiplasty platform combining advanced instrumentation and implants for improved efficiency and accuracy, planned for 2026 launch.
SuperBite Compression Screw System: New addition to portfolio, targeting the most common fixation method in foot and ankle surgery, expanding TAM by $300 million.
Speed XM Fusion System: Entry into mid-foot and hindfoot market, leveraging SpeedPlate technology for larger bone fusions, complementing SuperBite system.
Market Expansion with New Products: Expanded serviceable TAM with new product launches, targeting untapped opportunities in bunion correction and adjacent procedures.
Increased Surgeon Adoption: Over 25% of surgeon base adopted new bunion systems within two quarters of launch, driving procedure volume growth.
Improved Financial Metrics: Reduced cash burn by 46% in 2025 compared to 2024, with plans to further reduce by 50% in 2026.
Adjusted EBITDA Improvement: Achieved a 64% improvement in adjusted EBITDA loss in 2025 compared to 2024.
Comprehensive Bunion Solutions: Transitioned from a Lapiplasty-focused company to a comprehensive bunion solutions provider, addressing all bunion deformity categories.
Focus on TAM Expansion: Strategically targeting new procedural adjacencies and expanding product offerings to grow wallet share.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Economic Conditions and Consumer Sentiment: Broader economic conditions and softer consumer sentiment are creating headwinds, impacting case volume growth and revenue.
Revenue Decline: The company expects a revenue decline of 6% to 0% for full year 2026 compared to 2025, with declines continuing until the fourth quarter.
Product Mix Shift: A shift in revenue mix towards lower-priced products is negatively affecting overall revenue.
Litigation Expenses: Increased litigation expenses contributed to higher operating costs in the fourth quarter of 2025.
Restructuring Charges: Restructuring charges have increased operating expenses, adding financial pressure.
Cash Burn: Although cash burn has been reduced, the company still anticipates using significant cash in 2026, which could strain financial resources.
Adjusted EBITDA Loss: The company expects an adjusted EBITDA loss of $4 million to $6 million for full year 2026, compared to a loss of $3.9 million in 2025.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects full year 2026 revenue to be in the range of $200 million to $212 million, representing a decline of 6% to 0% compared to full year 2025. Revenue declines are expected to continue until the seasonally strongest fourth quarter, which will be driven by accelerating case volumes, the lapping of mix shift dynamics, and contributions from planned 2026 product launches.
Quarterly Revenue Trends for 2026: The company anticipates Q1 2026 revenue to step down approximately 27% compared to Q4 2025. Year-over-year growth rates are expected to improve each quarter thereafter.
Adjusted EBITDA for 2026: The company expects a loss in adjusted EBITDA in the range of $4 million to $6 million for the full year 2026, compared to a loss of $3.9 million in full year 2025.
Cash Usage Reduction for 2026: The company anticipates a reduction in cash usage of approximately 50% for full year 2026 compared to full year 2025.
Product Launches in 2026: The company plans to launch two new products in the back half of 2026: the SuperBite variable pitch compression screw system and the Speed XM Fusion system, which are expected to expand the total addressable market (TAM) by an estimated $300 million.
Lapiplasty Platform Enhancements: In 2026, the company plans to commercialize the next-generation Lapiplasty platform, known as Lapiplasty Lightning, which includes advanced instrumentation and implants designed to improve efficiency and accuracy.
Market Expansion and TAM Growth: The company aims to grow its customer wallet share and expand its TAM by introducing new products and entering new procedural adjacencies, such as the mid-foot and hindfoot segments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your thoughts on the foot and ankle market's softness in 2025 and its impact on your guidance for 2026?
A:The foot and ankle market was softer in 2025 due to deferrals of cases and a decline in bunion surgical volume. Despite this, the company saw an increase in Q4 case volumes, indicating market share gains. For 2026, they expect case volume growth offset by product ASP mix-related headwinds in the first half, with improvements in Q3 and Q4 due to new product launches and sales rep ramp-ups.
Q:How will the scaling of the biologics portfolio impact operating margins?
A:The biologics portfolio expansion is expected to provide additional revenue without negatively impacting margins. The company is optimistic about the upside potential of this broader portfolio.
Q:Can you provide more details about the new products expanding the TAM, such as SuperBite screws and Speed XM?
A:SuperBite screws and Speed XM have been in development for about 18 months, involving elite surgeons and extensive testing. SuperBite screws add breadth to the sales reps' offerings, while Speed XM targets larger bones in the foot, enabling the company to tap into new high ASP procedures.
Q:What are surgeons' initial reactions to the new osteotomy solutions?
A:Surgeons are showing strong interest in the MTP fusion system and MIS products. The MTP fusion system addresses a significant segment of bunion patients with arthritis, while the MIS products (Nanoplasty and Percuplasty) cater to different surgeon proficiency levels, offering comprehensive and efficient solutions.
Q:What factors influence the high and low ends of your guidance range?
A:The guidance range accounts for market uncertainties, macroeconomic headwinds, and the uptake of new products. The low end reflects potential market challenges, while the high end depends on greater adoption of new products and increased case volumes.
Q:How is the sales force adapting to the broader product portfolio?
A:The sales force has been trained extensively to handle the expanded portfolio. The focus remains on bunion-related procedures, with new products addressing adjacent procedures that align with customer demand. The company ensures that the sales force is equipped to meet these needs effectively.
Q:How does the broader product line and expanding sales force affect competitive dynamics?
A:The expanded product line and sales force position the company as a comprehensive provider for bunion-related needs. High engagement at industry events and strong surgeon interest indicate a competitive advantage, with the company emphasizing training and support to ensure successful adoption.
Q:What initiatives are planned to improve cash flow and reduce cash burn in 2026?
A:The company plans to leverage cost reductions from 2025, optimize medical education and DTC investments, and reduce CapEx related to instrumentation trays. These measures aim to reduce cash burn by 50% while maintaining focus on sales growth and profitability.
Q:What is the long-term growth outlook for the company?
A:The company aims to grow faster than the mid-single-digit growth rate of the foot and ankle market, leveraging its focused product portfolio and direct sales force. The broader portfolio and market share gains are expected to drive sustainable growth.
Q:How is the strategy for MIS osteotomy progressing?
A:The MIS osteotomy strategy is progressing well, with 25% of customers adopting the new technologies within two quarters. The company expects continued growth in adoption and positive reception from surgeons, supported by training and hands-on experiences.
Q:What assumptions underpin the guidance for 2026, particularly regarding MIS osteotomy and Lapiplasty?
A:The guidance assumes reasonable uptake of MIS osteotomy, MTP fusion, and new Lapiplasty products, along with contributions from upcoming product launches like SuperBite screws and Speed XM. The company is focused on executing this plan effectively.
Q:How does the rollout of new products affect the strategy for penetrating the market?
A:The new products aim to deepen penetration within the existing surgeon base while also attracting new surgeons. The focus is on leveraging the large customer base and addressing unmet needs with innovative solutions.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the long-term sustainable growth rate, offering only general statements about market dynamics and their competitive positioning without specific numerical targets or detailed strategies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Fusion
IntelliGuide
Lightning
MIS approach
MTP
Speed XM
Speed implant
SpeedPlate fixation
SuperBite
adjacency
biologics
bone
case volume
cash burn
category
condition
confidence strategy
customer wallet
decline
digit rate
fixation technology
instrumentation
mid
mix shift
offering customer
offering wallet
plane
plate
platform
product launch
product offering
recurrence
screw system
segment
strategy place
user
wallet TAM
TMCI Transcript
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Unknown5-8
Despite a decline in revenue and widening losses, the company has demonstrated effective cash management and cost reduction. The upcoming product launches and market expansion plans could positively impact future growth. However, persistent ASP headwinds and competitive pressures present risks. The Q&A session revealed mixed sentiments, with management providing optimistic guidance but avoiding specifics on market penetration. Given the balance of positive and negative factors, the stock price is likely to remain stable in the near term, resulting in a neutral sentiment.
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call reveals mixed signals. While the company shows improved financial health, with reduced losses and cash use, and has a strong product pipeline, the market is facing softness and uncertainties. Although there is optimism about new product adoption and sales force expansion, the guidance remains cautious, reflecting macroeconomic headwinds. Furthermore, management's lack of clarity on long-term growth rates adds to uncertainty. The positive aspects are balanced by potential risks, leading to a neutral sentiment.
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents mixed signals: while revenue and adjusted EBITDA show improvement, the net loss has increased, and the core Lapiplasty business is facing challenges due to shifting preferences towards minimally invasive procedures. Additionally, management's refusal to provide 2026 guidance and reliance on general optimism without specifics raises concerns. The decrease in gross margin and increased operating expenses further contribute to a negative sentiment, despite progress in profitability and liquidity management.
TMCI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
